Search Within

Hematology-Oncology Fellows

  1. "Anton Safonov"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (13)
Groups
  1. GME, Medicine (29)
  2. Graduate Medical Education (29)
  3. Weinberg Fellows (29)
  4. Breast Medicine Service (28)
  5. Department of Medicine (28)
  6. Solid Tumor Oncology Division (28)

More Groups

People
  1. Anton Safonov (29)
  2. Pedram Razavi (24)
  3. Sarat Chandarlapaty (16)
  4. Jorge Reis-Filho (11)
  5. Mark Robson (11)
  6. Larry Norton (9)

More People

Years
  1. 2025 (2)
  2. 2024 (14)
  3. 2023 (4)
  4. 2022 (6)
  5. 2021 (2)
  6. 2020 (1)
Publications
  1. Journal of Clinical Oncology (12)
  2. Nature Communications (3)
  3. Annals of Oncology (2)
  4. Cancer Research (2)
  5. Cell (2)
  6. Blood (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. Nature Publishing Group (5)
  3. Cell Press (4)
  4. American Association for Cancer Research (3)
  5. Oxford University Press (2)
  6. American Society of Hematology (1)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response
    Meeting Abstract

    Mai, N.; Safonov, A.; Marra, A.; Chen, Y.; Chandarlapaty, S.; Razavi, P.; Plitas, G.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases
    Meeting Abstract

    Khatri, I. S.; Eichholz, J.; Boe, L. A.; Safonov, A.; Smith, D. R.; Ferraro, E.; Shen, J.; Imber, B. S.; Yu, Y.; Yamada, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer
    Meeting Abstract

    Shen, S.; Safonov, A.; Bromberg, M.; Chen, Y.; Ahmed, M.; Razavi, P.; Jhaveri, K. L.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
    Journal Article

    Tai, Y.; Chow, A.; Han, S.; Coker, C.; Ma, W.; Gu, Y.; Estrada Navarro, V.; Kandpal, M.; Hibshoosh, H.; Kalinsky, K.; more...
    EMBO Molecular Medicine (2024)

    Fulltext@MSK | Save
  • Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes
    Journal Article

    Chew, S. M.; Ferraro, E.; Safonov, A.; Chen, Y.; Kelly, D.; Razavi, P.; Robson, M.; Seidman, A. D.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Pan-cancer assessment of the impact of intronic variants on cancer development and progression
    Meeting Abstract

    Safonov, A.; Mehine, M.; Ceyhan-Birsoy, O.; Brown, D.; Bandlamudi, C.; Forbes, A.; Gazzo, A.; Selenica, P.; Shen, R.; Khurana, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer
    Journal Article

    Kim, S.; Armand, J.; Safonov, A.; Zhang, M.; Soni, R. K.; Schwartz, G.; McGuinness, J. E.; Hibshoosh, H.; Razavi, P.; Kim, M.; more...
    Cell Reports (2023)

    Fulltext@MSK | Save
  • Large-scale clinicogenomic models of solid tumor CNS metastasis
    Meeting Abstract

    Jee, J.; Luthra, A.; Fong, C.; Pichotta, K.; Tran, T.; Altoe, M.; Miller, A.; Shen, R.; Berger, M. F.; Sanchez-Vega, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment
    Meeting Abstract

    Wander, S. A.; Weipert, C. M.; Liao, J.; Safonov, A.; Zhang, N.; Bardia, A.; Razavi, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save